anti-cd22/topoisomerase i inhibitor antibody-drug conjugate azd4512
Generic: Anti-CD22/Topoisomerase I Inhibitor Antibody-drug Conjugate AZD4512
anti-cd22/topoisomerase i inhibitor antibody-drug conjugate azd4512: 1 clinical trial tracked.
anti-cd22/topoisomerase i inhibitor antibody-drug conjugate azd4512 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-cd22/topoisomerase i inhibitor antibody-drug conjugate azd4512, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)
Primary endpoint: Percentage of participants with dose-limiting toxicities (DLTs)
Interventionalopen91 targetStarted 2025-09Completion 2028-0322 sites · Australia, China, Italy, Japan…AstraZeneca